DBCG trial 89B comparing adjuvant CMF and ovarian ablation: Similar outcome for eligible but non-enrolled and randomized breast cancer patients

References

• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–17.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 1996;348:1189–96.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, et al. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: From a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol 2006; 24: 4956–62
   PubMed Web of Science ®Google Scholar
• Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993;341:1293–8.
   PubMedGoogle Scholar
• Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711–23
   PubMed Web of Science ®Google Scholar
• Brincker H, Rose C, Rank F, Mouridsen HT, Jakobsen A, Dombernowsky P, et al. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol 1987; 5: 1771–8
   PubMed Web of Science ®Google Scholar
• Groenvold M, Fayers PM, Petersen MA, Mouridsen HT. Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: Impact on health-related quality of life in a randomized trial. Breast Cancer Res Treat 2006; 98: 275–84
   PubMedGoogle Scholar
• Rothwell PM. Treating individuals 2. Subgroup analysis in randomized controlled trials: Importance, indications, and interpretation. Lancet 2005; 365: 176–86
   PubMed Web of Science ®Google Scholar
• Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, et al. Generalizability of cancer clinical trial results: Prognostic differences between participants and non participants. Cancer 2006; 106: 2452–8
   PubMedGoogle Scholar
• Steg PG, Lopez-Sendon J, Lopez de SE, Goodman SG, Gore JM, Anderson FA, et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007; 167: 68–73
   PubMedGoogle Scholar
• Bloom J, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359–77
   PubMed Web of Science ®Google Scholar
• Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmussen BB, et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 1990; 26: 442–9
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trial 1996; 17: 343–6
   PubMedGoogle Scholar
• Andersen KW, Mouridsen HT. Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol 1988; 27: 627–47
   PubMed Web of Science ®Google Scholar
• Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review. Lancet 2004; 363: 263–70
   PubMed Web of Science ®Google Scholar
• Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD. Systematic review to determine whether participation in a trial influences outcome. BMJ 2005; 330: 1175–81
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thurlimann B, Senn HJ. First--select the target: Better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006; 17: 1772–6
   PubMed Web of Science ®Google Scholar
• Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”. J Clin Epidemiol 2001; 54: 217–24
   PubMed Web of Science ®Google Scholar